Inventiva S.A (IVA): UBS sees a 70–80%+ probability that Inventiva’s lanifibranor delivers a competitive Phase III MASH result.

Overview

UBS previews Inventiva’s pivotal NATiV3 Phase III trial of oral pan-PPAR agonist lanifibranor in F2/F3 MASH. The institution argues that prior efficacy, the Phase III design, and a manageable safety profile support a high probability of a positive readout, expected in October or November 2026.

Core views

UBS’s central view is that lanifibranor has a 70–80%+ probability of delivering a competitive approximately 18% placebo-adjusted treatment effect on NATiV3’s dual primary endpoint: both MASH resolution and at least one stage of fibrosis improvement. Its simulation assigns a roughly 35–40% chance of a 24%+ delta and uses a 22% base case. The analysis assumes a 30–32% response rate in the treatment arm and a 7–8% placebo response rate before GLP-1 drop-ins. Historical MASH trials generally show dual-endpoint placebo response below 10%; while NATiV3’s 72-week duration may allow fibrosis more time to improve versus the 24-week Phase IIb NATIVE study, it also raises discontinuation and missing-data risk. The report argues that the Phase III population should not materially weaken efficacy translation from Phase II. NATiV3 uses the same dose and has enrolled only F2/F3 patients, with F3 representing 67% versus 35% in Phase II. UBS notes that the Phase II F2/F3 subgroup produced a slightly higher delta than the all-comer population, suggesting F1 patients did not drive the earlier result and that the greater F3 weighting could be neutral to slightly favorable. The primary endpoint is stringent because placebo patients rarely achieve both fibrosis improvement and MASH resolution. UBS treats approximately 9–10% GLP-1 drop-ins as a key conservatism: if predominantly in the placebo arm, they could add about 2 percentage points to placebo response, taking it toward 9–10% and reducing the efficacy delta by about 2 percentage points. It nevertheless argues that lanifibranor and GLP-1 therapies have orthogonal mechanisms and cites post-hoc Rezdiffra data as reassurance that GLP-1 use should not interfere materially with lanifibranor efficacy. UBS differentiates lanifibranor from traditional TZDs and full PPARγ agonists. Lanifibranor activates PPARα, PPARβ/δ and PPARγ in a balanced manner with attenuated PPARγ activity; UBS believes this can retain antifibrotic and metabolic activity while reducing PPARγ-linked edema, weight gain and heart-failure risk. In NATIVE, peripheral edema occurred in 6.0% at 800 mg and 8.4% at 1,200 mg, versus 2.5% on placebo, but UBS describes most cases as mild and manageable; drug-related edema was about 2.4%. One mild cardiac-failure event occurred in the 1,200 mg group and a similar event occurred on placebo. The report contrasts this with PROactive, where pioglitazone serious heart-failure events were 5.7% versus 4.1% on placebo. UBS further cites weight gain that plateaued around weeks 24–36 in blinded NATiV3 interim data, no associated deterioration in liver, metabolic or cardiovascular markers, repeated independent DMC reviews of more than 1,000 patients without a protocol change, and exclusion of patients at greatest fluid-overload risk. It acknowledges that stable coronary disease, prior myocardial infarction, diabetes, obesity and other cardiometabolic comorbidities may still be represented. On timing, the final NATiV3 patient completed the 72-week treatment period in early September. UBS estimates 4–8 weeks for database lock and cleaning, pointing to an October–November readout. It highlights the October 5 AASLD abstract embargo lift and the November 5–9 AASLD 2026 meeting as events to monitor, while considering topline results before the conference reasonably possible. UBS sees commercial differentiation in oral administration and efficacy. It estimates approximately US$1.5bn peak annual US sales and US$2.5bn globally for lanifibranor, versus a MASH market expected to reach at least US$15bn by the mid-2030s. The report cites Rezdiffra’s approximately US$360m+ quarterly sales, above a roughly US$1.5bn annualized run rate, and consensus 2035 sales of about US$7.5bn; UBS’s lanifibranor peak-sales assumption is about one-third of that level. The institution argues that positive Phase III efficacy with tolerable safety could establish a differentiated clinical profile and increase strategic interest from partners seeking cardiometabolic and hepatology exposure. UBS reiterates Buy and a US$12 target. The valuation applies a 75% probability of success to approximately US$2.5bn risk-adjusted peak sales and a 2.0x peak-sales multiple. Its target-price share-count assumption is 455m shares, comprising 434m fully diluted shares including 77m Tranche 3-associated shares contingent on successful Phase III data, plus an assumed approximately US$240m concurrent Q4 follow-on financing at about US$12 per share. Reported H1 2026 cash and equivalents of €166m plus €68m of short-term deposits are expected to fund the company through Q2 2027.

Analysis framework

UBS reviews lanifibranor’s mechanism, Phase II efficacy and safety evidence, then tests whether NATiV3 design differences, GLP-1 use, placebo response, treatment duration, and missing data could change Phase III outcomes. It uses scenario simulations for the dual-endpoint delta and probability of success, compares safety with historical TZD evidence, evaluates commercial positioning against MASH therapies, and values Inventiva using probability-adjusted peak sales and a peak-sales multiple.

Methodology notes

• Industry AnalysisSupply-demand framework

  MASH market and competitive-positioning analysis

  UBS assesses lanifibranor’s potential sales by considering the projected MASH market size, competitor efficacy and product characteristics, including oral administration and safety.

• Valuation methodsPS valuation

  Probability-adjusted peak-sales multiple valuation

  UBS applies a 2.0x multiple to probability-adjusted peak sales, then incorporates cash, dilution and financing assumptions to derive its price target.

• Other

  Illustrative Phase III probability-of-success simulation and sensitivity analysis

  UBS models drug and placebo response-rate assumptions, including GLP-1 drop-in effects, to estimate the likelihood of different dual-endpoint treatment-effect deltas.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Inventiva S.A (IVA)

  Primary covered company; its value is tied to lanifibranor’s Phase III MASH readout and commercial potential.

  Strengths

  Oral balanced pan-PPAR mechanism, prior efficacy evidence, FDA Breakthrough Therapy Designation, and an anticipated differentiated risk-benefit profile.

  Weaknesses

  Clinical-stage profile with valuation dependent on a pivotal trial and future commercialization.

  Comparison

  UBS estimates potential 18–24%+ placebo-adjusted efficacy versus approximately 11% for Rezdiffra and approximately 17% for semaglutide.

  Risks

  Weaker-than-expected clinical data, development delays, safety or tolerability concerns, GLP-1-related placebo effects, missing data, and dilution from assumed financing.

Key data

• Estimated probability of success70–80%+Probability that lanifibranor achieves an approximately 18% placebo-adjusted dual-endpoint treatment effect.
• Base-case dual-endpoint delta22%Fibrosis improvement plus MASH resolution versus placebo.
• Probability of 24%+ delta~35–40%UBS simulation outcome.
• Treatment-arm response assumption30–32%Used in UBS’s Phase III scenario analysis.
• Placebo response assumption7–8%Before GLP-1 drop-ins; UBS estimates an effective 9–10% under its conservative drop-in scenario.
• NATiV3 timingOctober–November 2026UBS estimate after final patient completed 72-week treatment in early September.
• Lanifibranor peak sales~US$2.5bn globallyUBS estimate; about US$1.5bn annually in the US.
• Price targetUS$12.00Based on 75% probability of success, ~US$2.5bn risk-adjusted peak sales and a 2.0x peak-sales multiple.
• Cash runwayThrough Q2 2027Based on reported €166m cash and equivalents plus €68m short-term deposits at H1 2026.

Impact & implications

UBS believes a positive NATiV3 result could validate a differentiated oral MASH therapy with competitive efficacy and manageable safety, supporting commercial uptake and potentially increasing strategic interest. Its valuation remains highly dependent on clinical success, the assumed sales opportunity, financing, and dilution assumptions.

Risks

• Longer 72-week follow-up may increase discontinuations and missing data, which can dilute treatment-arm performance on an intention-to-treat basis.
• GLP-1 drop-ins, if disproportionately concentrated in the placebo arm, could inflate placebo response by about 2 percentage points and reduce the measured efficacy delta.
• Peripheral edema and weight gain remain on-target PPARγ-related effects, and cardiovascular risk is not fully excluded despite NATiV3 entry criteria.
• UBS identifies weaker clinical data, development delays, and safety or tolerability concerns as downside risks to valuation.
• The target-price calculation assumes a concurrent approximately US$240m Q4 financing and associated dilution.

What to watch

• The Phase III NATiV3 topline readout, which UBS expects could occur in October or November 2026.
• AASLD 2026 abstract release, with embargo lift expected at 8 AM MT on October 5, and the November 5–9 conference.
• The reported dual-endpoint delta versus UBS’s 18% base success bar and 24% upside case.
• Heart-failure events, edema, weight trajectory, discontinuations, and missing-data rates in Phase III.
• The distribution and impact of GLP-1 drop-ins across trial arms.
• Cash runway through Q2 2027 and the assumed follow-on financing.